HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiplaque Claims Spectrum Outlined By WhiteHill

This article was originally published in The Rose Sheet

Executive Summary

Products carrying antiplaque-only claims should be permitted in the OTC antigingivitis/antiplaque monograph, WhiteHill Oral Technologies states in Nov. 24 comments to FDA
Advertisement

Related Content

Antiplaque Essential Oil In Vitro Plus In Vivo Test Requirement Urged By Pfizer
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR
FDA Should Allow "Qualified" Plaque-Only Cosmetics Claims, WhiteHill Says
Advertisement
UsernamePublicRestriction

Register

RS011722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel